Search clinical trials for: PET amyloid tracer (Florbetapir F18 AV45 F18

Total 568 results

Assistance Publique Hopitaux De Marseille

Unknown

Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).

Alzheimer's Disease

France
Samuel Gandy

Completed

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

Traumatic Brain Injury | Mild Cognitive Impairment | Chronic Traumatic Encephalopathy

United States
Medical College of Wisconsin

Terminated

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Cardiac Amyloidosis

United States
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Brigham and Women's Hospital

Terminated

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Cardiac Amyloidosis

United States
Avid Radiopharmaceuticals

Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Chang Gung Memorial Hospital

Unknown

Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study (Alzheimer's)

Alzheimer's Disease

Taiwan
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; Avid Radiopharmaceuticals

Completed

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (COGHIC-AV45)

Intracerebral Hemorrhage

France
Avid Radiopharmaceuticals
Eli Lilly and Company; PRA Health Sciences

Completed

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Alzheimer Disease | Cognition Disorders

United States
Assistance Publique - Hôpitaux de Paris

Completed

Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging (AVILL)

Alzheimer Disease

France
Duke University

Withdrawn

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

Traumatic Brain Injury | Posttraumatic Stress Disorder | Alzheimer Dementia

United States
Universidad Central del Caribe
University of Puerto Rico

Not yet recruiting

B-amyloid as a Marker for GBM Bioimaging

Glioblastoma

Puerto Rico
Northwestern University

Completed

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia (PPA)

Dementia | Alzheimer Disease | Primary Progressive Aphasia

United States
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Northwestern University

Completed

Florbetaben PET Imaging in PPA

Alzheimer Disease | Primary Progressive Aphasia

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 Autopsy Study

Alzheimer's Disease

United States, Australia
Avid Radiopharmaceuticals

Completed

Tau Screening Study in Patients With Early Symptomatic AD

Alzheimer Disease

United States, Canada
Brigham and Women's Hospital
Boston University; U.S. Army Medical Research and Development Command

Completed

Tau Imaging of Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Eli Lilly and Company

Active, not recruiting

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) (GERAS-US)

Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Tau Screening Study in Subjects With Early Symptomatic AD

Alzheimer Disease

United States
St. Joseph's Hospital and Medical Center, Phoenix
Banner Alzheimer's Institute, Phoenix; Translational Genomics Research Institute...

Completed

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

Down Syndrome | Alzheimer's Dementia

United States
The Cleveland Clinic
Avid Radiopharmaceuticals

Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis

United States
Mayo Clinic

Completed

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Amyloidosis

United States
Thomas Hope

Active, not recruiting

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms (UC-GlioFET)

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II Glioma

United States
Avid Radiopharmaceuticals

Completed

Flortaucipir PET Imaging in Subjects With FTD

Frontotemporal Dementia

United States
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Flortaucipir F 18

Depression | Traumatic Brain Injury | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment

Search clinical trials for: PET amyloid tracer (Florbetapir F18 AV45 F18

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations